ApprovalsOther Diseases September 18, 2023 UK’s NICE recommends QUVIVIQ to treat chronic insomnia in adults By PBR Staff Writer A Final Draft Guidance (FDG) has been issued for QUVIVIQ for the treatment of these patients with symptoms lasting for three nights or more per week for at
Drug Discovery September 15, 2023 Nona and BeiGene agree to expand antibody discovery partnership By PBR Staff Writer Through the collaboration, BeiGene can access Nona’s fully human transgenic mice platform, Harbour Mice. In 2018, BeiGene received the rights to leverage the Harbour Mice heavy chain (H2L2)
Drug DiscoveryResearch & Development September 14, 2023 Synaffix, ABL Bio partner to develop bispecific ADCs By PBR Staff Writer Under the agreement, Synaffix will be eligible for an upfront payment, milestone payments along with tiered royalties on net sales of resulting products. The company will also produce
Drug Discovery September 13, 2023 Salipro and Sumitomo Pharma sign partnership for drug discovery programme By PBR Staff Writer Under the partnership, the companies will reveal the drug candidate’s mechanism of action as well as pharmacological characterisation. Salipro Biotech CEO Jens Frauenfeld said: “We are excited to
Oncology September 12, 2023 Orano Med and Orbit partner for radionuclide therapies discovery By PBR Staff Writer As per the agreement terms, Orbit will discover peptide leads specific to targets related to certain tumours by deploying its bead-based peptide display engine. Orbit Discovery CEO Dr
RegulationOncology September 11, 2023 US FDA issues guidance for Citius’ lymphoma treatment BLA By PBR Staff Writer An engineered interleukin-2 (IL-2)-diphtheria toxin fusion protein, Lymphir is intended for relapsed or refractory CTCL patients following treatment with a minimum of one systemic therapy previously. As per
Oncology September 8, 2023 Procaps Group and BDR sign agreement for oncology molecules By PBR Staff Writer As per the agreement, Procaps will be responsible for activities related to registration, branding, marketing along with commercialisation throughout Latin America. Procaps submitted an initial set of eight
News September 7, 2023 Maruho enters licence deal with Journey Medical for Qbrexza By PBR Staff Writer Under the agreement, Maruho will be responsible for the development and commercialisation of Qbrexza in South Korea, Brunei, Cambodia, Indonesia, Hong Kong, Macau, Vietnam, Malaysia, Philippines, Thailand, Myanmar,
Drug Discovery September 6, 2023 United Italian Trading launches GERD drug in Singapore By PBR Staff Writer The latest move comes after signing an exclusive licence agreement with HK inno.N in November 2020. The agreement granted sublicensing rights to UITC for developing, marketing, and manufacturing
Production & Sales September 5, 2023 Novo Nordisk launches Wegovy for obese patients in UK By PBR Staff Writer The latest move is aimed at sharing the government’s objective to make obesity care accessible to patients with high unmet medical need. Through a controlled and limited launch,